CoChat

Do Small Molecules Activate the TrkB Receptor in the Same Manner as BDNF? Limitations of Published TrkB Low Molecular Agonists and Screening for Novel TrkB Orthosteric Agonists

Open access

The DOI matches its Crossref record; 53 of the 54 references it cites were found in a registry or an index.

Abstract

TrkB is a tyrosine kinase receptor that is activated upon binding to brain-derived neurotrophic factor (BDNF). To date, the search for low-molecular-weight molecules mimicking BDNF’s action has been unsuccessful. Several molecules exerting antidepressive effects in vivo, such as 7,8-DHF, have been suggested to be TrkB agonists. However, more recent publications question this hypothesis. In this study, we developed a set of experimental procedures including the evaluation of direct interactions, dimerization, downstream signaling, and cytoprotection in parallel with physicochemical and ADME methods to verify the pharmacology of 7,8-DHF and other potential reference compounds, and perform screening for novel TrkB agonists. 7,8 DHF bound to TrkB with Kd = 1.3 μM; however, we were not able to observe any other activity against the TrkB receptor in SN56 T48 and differentiated SH-SY5Y cell lines. Moreover, the pharmacokinetic and pharmacodynamic effects of 7,8-DHF at doses of 1 and 50 mg/kg were examined in mice after i.v and oral administration, respectively. The poor pharmacokinetic properties and lack of observed activation of TrkB-dependent signaling in the brain confirmed that 7,8-DHF is not a relevant tool for studying TrkB activation in vivo. The binding profile for 133 molecular targets revealed a significant lack of selectivity of 7,8-DHF, suggesting a distinct functional profile independent of interaction with TrkB. Additionally, a compound library was screened in search of novel low-molecular-weight orthosteric TrkB agonists; however, we were not able to identify reliable drug candidates. Our results suggest that published reference compounds including 7,8-DHF do not activate TrkB, consistent with canonical dogma, which indicates that the reported pharmacological activity of these compounds should be interpreted carefully in a broad functional context.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/ph14080704

Cites

53 of 53 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Results of primary screening using the MST technique. Screening of 987 compounds was performed by examination of signal amplitude between the unbound and bound state of the molecule and the exTrkB receptor. Compounds were screened in single-point MST at concentrations of 0.5 mM for small molecular compounds and 20 nM exTrkB. Compounds with amplitudes greater than 0.5 SD were selected for further analysis.
Figure 1 Results of primary screening using the MST technique. Screening of 987 compounds was performed by examination of signal amplitude between the unbound and bound state of the molecule and the exTrkB receptor. Compounds were screened in single-point MST at concentrations of 0.5 mM for small molecular compounds and 20 nM exTrkB. Compounds with amplitudes greater than 0.5 SD were selected for further analysis.CC BY · PubMed Central
Figure 2 Binding affinity values (Kd) determined using the MST technique. Threshold (dotted lines) for compound selection was set from 0.1 to 450 μM. Fifty-nine molecules from the pool of 113 tested compounds presented Kd values in the range 0.1–450 μM. Non-binding compounds are indicated on the graph as Kd = 0 μM.
Figure 2 Binding affinity values (Kd) determined using the MST technique. Threshold (dotted lines) for compound selection was set from 0.1 to 450 μM. Fifty-nine molecules from the pool of 113 tested compounds presented Kd values in the range 0.1–450 μM. Non-binding compounds are indicated on the graph as Kd = 0 μM.CC BY · PubMed Central
Figure 3 Orthosteric activity of compounds measured as the fold change of TrkB phosphorylation (Y706), determined by enzyme-linked fixed-cell immunoassay (ELFI) method in the SN56 T48 cell line. (A) Screening of 59 molecules led to the identification of 4 compounds with orthosteric activity against TrkB. Molecules with no orthosteric activity are marked on the graph as EC50 = 0 μM; (B) Representative dose–response curves for active TrkB agonist compounds; (C) Lack of activity against the TrkB receptor for several compounds described in the literature as TrkB agonists. Data are presented as mean ± SEM, n = 3.
Figure 3 Orthosteric activity of compounds measured as the fold change of TrkB phosphorylation (Y706), determined by enzyme-linked fixed-cell immunoassay (ELFI) method in the SN56 T48 cell line. (A) Screening of 59 molecules led to the identification of 4 compounds with orthosteric activity against TrkB. Molecules with no orthosteric activity are marked on the graph as EC50 = 0 μM; (B) Representative dose–response curves for active TrkB agonist compounds; (C) Lack of activity against the TrkB receptor for several compounds described in the literature as TrkB agonists. Data are presented as mean ± SEM, n = 3.CC BY · PubMed Central
Figure 4 Evaluation of ligand-induced TrkB dimerization by native electrophoresis. The exTrkB receptor was incubated with tested compounds (stoichiometry ratio, 1:1). Dimerization of exTrkB was monitored by sample separation in non-reducing conditions. The upper band (red arrow) corresponds to exTrkB dimers induced by ligand binding; the lower band (blue arrow) corresponds to exTrkB monomers.
Figure 4 Evaluation of ligand-induced TrkB dimerization by native electrophoresis. The exTrkB receptor was incubated with tested compounds (stoichiometry ratio, 1:1). Dimerization of exTrkB was monitored by sample separation in non-reducing conditions. The upper band (red arrow) corresponds to exTrkB dimers induced by ligand binding; the lower band (blue arrow) corresponds to exTrkB monomers.CC BY · PubMed Central
Figure 5 Evaluation of compounds’ activity on TrkB and downstream protein phosphorylation in the SN56 T48 cell line. (A) Representative immunoblots for proteins of interest (p-TrkB, p-PLCγ1, p-Akt1, and p-ERK1/2). Cells were treated with BDNF (100 ng/mL) or reference compounds (100 μM) for 15 min; (B) Representative immunoblots for proteins of interest. Cells were treated with BDNF (100 ng/mL; 10 ng/mL; 1 ng/mL) or tested compounds (100 μM; 10 μM; 1 μM) for 15 min. K252a (1 μM) was used 15 min before treatment with tested compounds (100 μM); (C,D) Densitometry analysis of immunoblots. Bars represent mean ± SEM, n = 3. Data were analyzed with one-way ANOVA followed by Dunnett’s post hoc test. * p < 0.05, ** p < 0.01 and *** p < 0.001 compared to the DMSO-treated group. # p < 0.05, ## p < 0.01 and ### p < 0.001 compared to the compound-treated group.
Figure 5 Evaluation of compounds’ activity on TrkB and downstream protein phosphorylation in the SN56 T48 cell line. (A) Representative immunoblots for proteins of interest (p-TrkB, p-PLCγ1, p-Akt1, and p-ERK1/2). Cells were treated with BDNF (100 ng/mL) or reference compounds (100 μM) for 15 min; (B) Representative immunoblots for proteins of interest. Cells were treated with BDNF (100 ng/mL; 10 ng/mL; 1 ng/mL) or tested compounds (100 μM; 10 μM; 1 μM) for 15 min. K252a (1 μM) was used 15 min before treatment with tested compounds (100 μM); (C,D) Densitometry analysis of immunoblots. Bars represent mean ± SEM, n = 3. Data were analyzed with one-way ANOVA followed by Dunnett’s post hoc test. * p < 0.05, ** p < 0.01 and *** p < 0.001 compared to the DMSO-treated group. # p < 0.05, ## p < 0.01 and ### p < 0.001 compared to the compound-treated group.CC BY · PubMed Central
Figure 6 Evaluation of the impact of selected compounds on TrkB and downstream protein phosphorylation in the RA-differentiated SH-SY5Y cell line. (A) Representative immunoblots for proteins of interest (p-TrkB, p-PLCγ1, p-Akt1, and p-ERK1/2). Cells were treated with BDNF (100 ng/mL; 10 ng/mL; 1 ng/mL) and tested compounds (100 μM; 10 μM; 1 μM) for 15 min. K252a (1 μM) was used 15 min before treatment with tested compounds (100 μM); (B) Densitometry analysis of immunoblots. Bars represent mean ± SEM, n = 3. Data were analyzed with one-way ANOVA followed by Dunnett’s post hoc test. * p < 0.05, ** p < 0.01, and *** p < 0.001 compared to DMSO-treated group. # p < 0.05, ## p < 0.01, and ### p < 0.001 compared to compound-treated group.
Figure 6 Evaluation of the impact of selected compounds on TrkB and downstream protein phosphorylation in the RA-differentiated SH-SY5Y cell line. (A) Representative immunoblots for proteins of interest (p-TrkB, p-PLCγ1, p-Akt1, and p-ERK1/2). Cells were treated with BDNF (100 ng/mL; 10 ng/mL; 1 ng/mL) and tested compounds (100 μM; 10 μM; 1 μM) for 15 min. K252a (1 μM) was used 15 min before treatment with tested compounds (100 μM); (B) Densitometry analysis of immunoblots. Bars represent mean ± SEM, n = 3. Data were analyzed with one-way ANOVA followed by Dunnett’s post hoc test. * p < 0.05, ** p < 0.01, and *** p < 0.001 compared to DMSO-treated group. # p < 0.05, ## p < 0.01, and ### p < 0.001 compared to compound-treated group.CC BY · PubMed Central
Figure 7 Cytoprotective effect of TrkB agonists in the RA-differentiated SH-SY5Y cell line. Cells were treated with the tested compound for 72 h before cell death was induced by addition of MPP+ (0.5 mM). The cytoprotective effect of the compounds was evaluated after cotreating the cells with the compounds and MPP+ for another 72 h. Cell viability was monitored using RealTime-Glo™ MT Cell Viability Assay. Bars represent mean ± SEM, n = 3. Data were analyzed with one-way ANOVA followed by Dunnett’s post hoc test. *** p < 0.001 compared to DMSO-treated group. ### p < 0.001 compared to control group.
Figure 7 Cytoprotective effect of TrkB agonists in the RA-differentiated SH-SY5Y cell line. Cells were treated with the tested compound for 72 h before cell death was induced by addition of MPP+ (0.5 mM). The cytoprotective effect of the compounds was evaluated after cotreating the cells with the compounds and MPP+ for another 72 h. Cell viability was monitored using RealTime-Glo™ MT Cell Viability Assay. Bars represent mean ± SEM, n = 3. Data were analyzed with one-way ANOVA followed by Dunnett’s post hoc test. *** p < 0.001 compared to DMSO-treated group. ### p < 0.001 compared to control group.CC BY · PubMed Central
Figure 8 Pharmacokinetic and pharmacodynamic profiles of 7,8-DHF in BALB/c mice. The concentration–time curve of 7,8-DHF and its metabolites (7-hydroxy-8-methoxyflavone and 8-hydroxy-7-methoxyflavone) in plasma and brain lysates after intravenous (A) and oral (B) administration. Data are expressed as mean ± SEM, n = 4. Western blot analysis of the phosphorylation of TrkB and selected downstream proteins in the frontal cortex (C) and hippocampus (D) after oral administration of 7,8-DHF.
Figure 8 Pharmacokinetic and pharmacodynamic profiles of 7,8-DHF in BALB/c mice. The concentration–time curve of 7,8-DHF and its metabolites (7-hydroxy-8-methoxyflavone and 8-hydroxy-7-methoxyflavone) in plasma and brain lysates after intravenous (A) and oral (B) administration. Data are expressed as mean ± SEM, n = 4. Western blot analysis of the phosphorylation of TrkB and selected downstream proteins in the frontal cortex (C) and hippocampus (D) after oral administration of 7,8-DHF.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 42

Metadata

Authors
Pankiewicz, P., Szybiński, M., Kisielewska, K., Gołębiowski, F., Krzemiński, P., Rutkowska-Włodarczyk, I., Moszczyński-Pętkowski, R., Gurba-Bryśkiewicz, L., Delis, M., Mulewski, K., Smuga, D., Dominowski, J., Janusz, A., Górka, M., Abramski, K., Napiórkowska, A., Nowotny, M., Dubiel, K., Kalita, K., Wieczorek, M., Pieczykolan, J., & Matłoka, M.
Affiliations
  • Medical University of Warsaw (PL)
  • Celon Pharma (Poland) (PL)
  • Structural Biology Center, International Institute of Molecular and Cell Biology, 02-109 Warsaw, Poland
  • International Institute of Molecular and Cell Biology (PL)
  • Instytut Biologii Doświadczalnej im. Marcelego Nenckiego (PL)
Corresponding author
Matłoka, Mikołaj
Venue
Pharmaceuticals
Publisher
MDPI AG
Published
2021-07-21
Volume
14
Issue
8
Pages
704
ISSN
1424-8247 (ISSN-L)
OpenAlex
W3186036424
Cited by
42
References
54
Citations by year
2026: 7 · 2025: 9 · 2024: 10 · 2023: 9 · 2022: 5 · 2021: 2
FWCI
3.00
Type
journal article
Language
en
Open access
Locations
  • Pharmaceuticals (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Narodowe Centrum Badań i Rozwoju (POIR.01.02.00-00-0020/17-00)
  • Ministerstwo Nauki i Szkolnictwa Wyższego (Doktorat Wdrożeniowy 50//DW/2017/01/1)
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Nerve injury and regeneration
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacological Receptor Mechanisms and Effects
Keywords
TrkB receptor, brain-derived neurotrophic factor, orthosteric agonists, receptor activation, pharmacokinetics, pharmacodynamics, receptor dimerization, downstream signaling, compound library screening, target selectivity, receptor tyrosine kinase

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.